DRG Epidemiology's coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…
Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of…
Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…
Market Outlook: Angiogenesis inhibitors continue to be the mainstay of first-line and second-line advanced or metastatic renal cell carcinoma. While PD-1 inhibitor, Opdivo entry in the second-line…
Market Outlook Squamous cell carcinoma of the head and neck ( SCCHN ) is an anatomically and biologically heterogeneous disease, which has historically proven a complex challenge for drug…
Immune checkpoint inhibitors (ICIs), including Bristol-Myers Squibb’s Opdivo and Yervoy and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies for several cancers, notably…
The renal cell carcinoma drug market in Europe is increasingly competitive. Angiogenesis inhibitors (such as Pfizer’s Sutent and Novartis’s Votrient) and mTOR inhibitors (Pfizer’s Torisel and…
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The…
The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA…
Prior to 2016, the therapeutic landscape for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) had only benefited from the introduction of one novel treatment, Erbitux,…
Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…
From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing…